Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11246667 | 0.84 | CYP1A2 (0.58) | CYP1A2KDM4ENPC1LMNATP53 | |
| SCHEMBL9538995 | 0.82 | CYP1A2 (0.61) | CYP1A2KDM4ENPC1LMNATP53 | |
| SCHEMBL7061128 | 0.82 | PTGS2 (0.57) | CYP1A2KDM4ENPC1LMNATP53 | |
| SCHEMBL3716715 | 0.81 | TAAR1 (0.68) | CYP1A2KDM4ENPC1LMNATP53 | |
| SCHEMBL14783441 | 0.81 | HTR2A (0.56) | CYP1A2KDM4ENPC1LMNATP53 | |
| SCHEMBL16024600 | 0.81 | HTR2A (0.56) | CYP1A2KDM4ENPC1LMNATP53 | |
| SCHEMBL19506648 | 0.81 | HTR2A (0.56) | CYP1A2KDM4ENPC1LMNATP53 | |
| SCHEMBL15802596 | 0.81 | CYP1A2 (0.59) | CYP1A2KDM4ENPC1LMNATP53 | |
| SCHEMBL28131897 | 0.81 | CYP1A2 (0.55) | CYP1A2KDM4ENPC1LMNATP53 | |
| Hydrochloric Acid SCHEMBL11267009 | 0.80 | TAAR1 (0.66) | CYP1A2KDM4ENPC1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155053-B2 | Method for obtaining novel derivatives of naphthalene for the in vivo diagnosis of Alzheimer's disease | CENTRO DE NEUROCIENCIAS DE CUBA (CU) | 2018-12-18 | — | — | US | disclosed |
| EP-2860169-B1 | Method for obtaining novel derivatives of naphtalene for the in vivo diagnosis of Alzheimer's disease | CENTRO DE NEUROCIENCIAS DE CUBA (CU) | 2018-08-29 | — | — | EP | disclosed |
| US-9764047-B2 | Method for obtaining novel derivatives of naphthalene for the in vivo diagnosis of alzheimer's disease | CENTRO DE NEUROCIENCIAS DE CUBA (CU) | 2017-09-19 | — | — | US | disclosed |
| US-20150217005-A1 | METHOD FOR OBTAINING NOVEL DERIVATIVES OF NAPHTHALENE FOR THE IN VIVO DIAGNOSIS OF ALZHEIMER'S DISEASE | SABLON CARRAZANA MARQUIZA (CU) | 2015-08-06 | — | — | US | disclosed |
| US-20150217005-A1 | METHOD FOR OBTAINING NOVEL DERIVATIVES OF NAPHTHALENE FOR THE IN VIVO DIAGNOSIS OF ALZHEIMER'S DISEASE | SABLON CARRAZANA MARQUIZA (CU) | 2015-08-06 | — | — | US | disclosed |
| EP-2860169-A2 | Method for obtaining novel derivatives of naphtalene for the in vivo diagnosis of Alzheimer's disease | Centro De Neurociencias De Cuba (CU) | 2015-04-15 | — | — | EP | disclosed |
| US-20120321560-A1 | Method for Obtaining Novel Derivatives of Naphthalene for the In Vivo Diagnosis of Alzheimer's Disease | CENTRO DE NEUROCIENCIAS DE CUBA (CU) | 2012-12-20 | — | — | US | disclosed |
| EP-2436666-A2 | METHOD FOR OBTAINING NOVEL DERIVATIVES OF NAPHTALENE FOR THE IN VIVO DIAGNOSIS OF ALZHEIMER 'S DISEASE | Centro De Neurociencias De Cuba (CU) | 2012-04-04 | — | — | EP | disclosed |
| EP-2436666-A2 | METHOD FOR OBTAINING NOVEL DERIVATIVES OF NAPHTALENE FOR THE IN VIVO DIAGNOSIS OF ALZHEIMER 'S DISEASE | Centro De Neurociencias De Cuba (CU) | 2012-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120321560-A1 | Method for Obtaining Novel Derivatives of Naphthalene for the In Vivo Diagnosis of Alzheimer's Disease | SLC43A1, SLCO2B1, SLCO2A1 | CYP1A2 1183/4885KDM4E 3934/4885NPC1 128/4885 |
| US-20150217005-A1 | METHOD FOR OBTAINING NOVEL DERIVATIVES OF NAPHTHALENE FOR THE IN VIVO DIAGNOSIS OF ALZHEIMER'S DISEASE | SLC43A1, SLCO2B1, FABP7 | CYP1A2 1126/4885KDM4E 4008/4885NPC1 147/4885 |
| US-10155053-B2 | Method for obtaining novel derivatives of naphthalene for the in vivo diagnosis of Alzheimer's disease | SLC43A1, SLCO2B1, FABP7 | CYP1A2 1126/4885KDM4E 4008/4885NPC1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.